The stock will trade on pipeline milestones, not quarterly financials. Key catalysts: bitopertin APOLLO topline data (Q4 2026), DISC-0974 ASCO presentation (June 2026), and DISC-3405 data (Q4 2026). Monitor for FDA Type A meeting outcome in Q2 2026.
IRON drugs
IRON drug pipeline →Price Chart
Executive Summary
Disc Medicine reported Q1 2026 results with a net loss of $63.5M ($1.65/share), wider than the $34.1M loss in Q1 2025, driven by increased R&D and SG&A spending. The company completed enrollment in the Phase 3 APOLLO study for bitopertin (topline data expected Q4 2026) and maintains a strong cash position of $730M, funding operations into 2029. The wider loss and lack of revenue are consistent with a clinical-stage biotech, but the stock will move on pipeline catalysts, not the financials.
Key Financial Metrics
Key Facts
- Net loss of $63.5M for Q1 2026 vs $34.1M in Q1 2025
- Net loss per share of $1.65 vs $1.02 in Q1 2025
- Cash, cash equivalents, and marketable securities of $730.2M as of March 31, 2026
- Completed enrollment of Phase 3 APOLLO study for bitopertin in EPP; topline data expected Q4 2026
- Type A meeting with FDA scheduled for Q2 2026 to review bitopertin resubmission approach
- Updated Phase 2 data for DISC-0974 in MF anemia selected for oral presentation at ASCO in June 2026
- Phase 2 study of DISC-3405 in PV and Phase 1b study in SCD progressing; data expected Q4 2026
Financial Impact
Net loss widened by $29.4M YoY to $63.5M; cash burn of ~$61M in Q1 2026
Risk Factors
- Bitopertin received a Complete Response Letter (CRL) from FDA in Feb 2026; approval path uncertain
- Widening net loss and increasing cash burn rate
- Clinical-stage biotech with no approved products or revenue
- Dilution risk from potential future equity offerings
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-205187 |
| Document: iron-20260505.htm | 0001193125-26-205187 |
| Document: 0001193125-26-205187-index-headers.html | 0001193125-26-205187 |
| Document: 0001193125-26-205187-index.html | 0001193125-26-205187 |
| Document: 0001193125-26-205187.txt | 0001193125-26-205187 |
| 8-K Data (Synthetic) | 0001193125-26-205187 |
Track record
43 reports on IRON
7 of 10 bullish or bearish reports moved the stock their way by T+20. Best: +20.07% at T+20 after the Sep 3, 2026 report. 11 of 16 went positive at some point.
Filters
- Nov 10, 20266d ago 144 Neutral 2/10 Entry $87.08 Now $76.59 −12.05% settles Dec 10
- Nov 5, 202611d ago 424B5 Bearish 5/10 Entry $78.91 Now $76.59 +2.94% settles Dec 7
- Nov 5, 202611d ago 8-K Neutral 5/10 No price data
- Nov 5, 202611d ago Press Release Bullish 7/10 Entry $78.47 Now $76.59 −2.40% settles Dec 4
- Nov 4, 202612d ago Press Release Neutral 3/10 Entry $83.28 Now $76.59 −8.03% settles Dec 3
- Nov 3, 202613d ago Institutional Cluster Neutral 3/10 Entry $81.16 Now $76.59 −5.63% settles Dec 2
- Oct 26, 202621d ago SC 13D/A Neutral 3/10 Entry $79.90 Now $76.59 −4.14% settles Nov 24
- Oct 22, 202625d ago 8-K Bearish 6/10 Entry $74.51 Now $76.59 −2.79% settles Nov 20
- Oct 21, 202626d ago 424B5 Bearish 6/10 Entry $75.03 Now $76.59 −2.08% settles Nov 19
- Oct 21, 202626d ago 144 Neutral 2/10 Entry $75.03 Now $76.59 +2.08% settles Nov 19
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers